Press "Enter" to skip to content

Biogen halts development of therapy for rare brain disease

The therapy, gosuranemab, failed to hit statistical significance in its main goal and did not demonstrate effectiveness on key secondary goals, when tested in patients with progressive supranuclear palsy.

Original source:

Also Read:   US scientist: 5-year trial period for new medicines needs to be reduced